PMID- 30903758
OWN - NLM
STAT- MEDLINE
DCOM- 20190809
LR  - 20210222
IS  - 2363-8915 (Electronic)
IS  - 2363-8915 (Linking)
VI  - 34
IP  - 1
DP  - 2019 Mar 19
TI  - The prevalence of potentially beneficial and harmful drug-drug interactions in 
      intensive care units.
LID - 10.1515/dmpt-2018-0034 [doi]
AB  - Background The present study was conducted with the aim of investigating the 
      prevalence of potentially beneficial and harmful drug-drug interactions (DDIs) in 
      intensive care units (ICUs). Methods The present cross-sectional prospective 
      study was conducted in two ICUs in Shahr-e Kord city, Iran. The study sample was 
      consisted of 300 patients. The Drug Interaction Facts reference text book [Tatro 
      DS. Drug interaction facts. St Louis, MO: Walters Kluwer Health, 2010.] was used 
      to determine the type and the frequency of the DDIs. Results The participants 
      consisted of 189 patients men and 111 women. The mean age of patients was 44.2 +/- 
      24.6 years. Totally, 60.5% of patients had at least one drug-drug interaction in 
      their profile. The total number of DDIs found was 663 (the mean of the total 
      number of drug-drug interactions was 2.4 interactions per patient). Of all the 
      663 interactions, 574 were harmful and others were beneficial. In terms of 
      starting time, 98 of the potential interactions were rapid and 565 of them were 
      delayed. In terms of severity, 511 of the potential interactions were moderate. 
      Some of the drugs in the patients' medical records including phenytoin, dopamine, 
      ranitidine, corticosteroid, dopamine, heparin, midazolam, aspirin, magnesium, 
      calcium gluconate, and antibiotics, the type of ventilation, the type of 
      nutrition and the duration of hospital stay were among the factors that were 
      associated with high risk of potential DDIs (p < 0.05). Conclusions The 
      prevalence of potentially beneficial and harmful DDIs, especially harmful 
      drug-drug interactions, is high in ICUs and it is necessary to reduce these 
      interactions by implementing appropriate programs and interventions.
FAU - Mehralian, Hossein Ali
AU  - Mehralian HA
AD  - Community Oriented Nursing and Midwifery Research Center, Shahrekord University 
      of Medical Sciences, Shahrekord, Iran.
FAU - Moghaddasi, Jafar
AU  - Moghaddasi J
AD  - Community Oriented Nursing and Midwifery Research Center, Shahrekord University 
      of Medical Sciences, Shahrekord, Iran.
FAU - Rafiei, Hossein
AU  - Rafiei H
AD  - Social Determinants of Health Research Center, Qazvin University of Medical 
      Sciences, Qazvin, Iran.
LA  - eng
PT  - Journal Article
DEP - 20190319
PL  - Germany
TA  - Drug Metab Pers Ther
JT  - Drug metabolism and personalized therapy
JID - 101653409
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Drug Interactions
MH  - Female
MH  - Humans
MH  - *Intensive Care Units
MH  - Iran
MH  - Male
MH  - Prospective Studies
OTO - NOTNLM
OT  - clinical pharmacology
OT  - critically ill patient
OT  - drug complications
OT  - harmful drug-drug interaction
EDAT- 2019/03/25 06:00
MHDA- 2019/08/10 06:00
CRDT- 2019/03/24 06:00
PHST- 2018/10/26 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/03/24 06:00 [entrez]
PHST- 2019/03/25 06:00 [pubmed]
PHST- 2019/08/10 06:00 [medline]
AID - dmpt-2018-0034 [pii]
AID - 10.1515/dmpt-2018-0034 [doi]
PST - epublish
SO  - Drug Metab Pers Ther. 2019 Mar 19;34(1). doi: 10.1515/dmpt-2018-0034.